Showing results (211-220 of 527) with videos related to
Sort By:
Pageof 53
Zeitschrift Fur Gastroenterologie|August 14, 2018
[Ustekinumab - Current position]Britta Siegmund, Christoph Högenauer, Gottfried Novacek, et al.Gut|October 15, 2011
Role of biological therapy for inflammatory bowel disease in developing countriesGerhard Rogler, Charles N Bernstein, Ajit Sood, et al.Clinical Nutrition ESPEN|May 27, 2022
Gut microbiome and circulating bacterial DNA ("blood microbiome") in a mouse model of total parenteral nutrition: Evidence of two distinct separate microbiotic compartmentsEliana Lucchinetti, Phing-How Lou, Philipp Lemal, et al.Journal of Crohn'S & Colitis|September 12, 2018
Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease-Related Colorectal Neoplastic Lesions: The Role of InflammationMagali Svrcek, Paula Borralho Nunes, Vincenzo Villanacci, et al.Inflammatory Bowel Diseases|January 30, 2007
Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patientsTanja Spoettl, Martin Hausmann, Frank Klebl, et al.Plos One|March 30, 2018
Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel diseaseFlorian Kamm, Ulrike Strauch, Frauke Degenhardt, et al.Plos One|September 5, 2018
Correction: Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel diseaseFlorian Kamm, Ulrike Strauch, Frauke Degenhardt, et al.Inflammatory Bowel Diseases|March 6, 2015
Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18Daniela B Engler, Irina Leonardi, Mara L Hartung, et al.Inflammatory Intestinal Diseases|April 14, 2021
Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease PatientsIlana Reinhold, Sena Blümel, Jens Schreiner, et al.Plos One|January 26, 2019
Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort StudyNina Roth, Luc Biedermann, Nicolas Fournier, et al.Pageof 53